CD8A and cancer: Furthermore, LOY is associated with adverse outcomes in patients with bladder cancer, and cancer cells exhibiting LOY have been shown to modify T-cell functionality, leading to exhaustion of CD8 + T cells in the tumor microenvironment and increasing their susceptibility to PD-1-targeted immunotherapy [28].